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TheexistenceofT-cellsubsetsnaturallycommittedtoperformimmunoregulationhasledtoenthusiasticeﬀortstoinvestigatetheir
role in the immunopathogenesis of transplantation. Being able to modulate alloresponses, regulatory T cells could be used as an
immunodiagnostic tool in clinical kidney transplantation. Thus, the measurement of Foxp3 transcripts, the presence of regulatory
T cells in kidney biopsies, and the phenotypic characterisation of the T-cell inﬁltrate could aid in the diagnosis of rejection and the
immunemonitoringandpredictionofoutcomesinkidneytransplantation.Interestingly,theadoptivetransferofregulatoryTcells
in animal models has been proven to downmodulate powerful alloresponses, igniting translational research on their potential use
as an immunomodulatory therapy. For busy transplant clinicians, the vast amount of information in the literature on regulatory
T cells can be overwhelming. This paper aims to highlight the most applicable research ﬁndings on the use of regulatory T cells
in the immune diagnosis and potential immunomodulatory therapy of kidney transplant patients. However, can we yet rely on
diﬀerential regulatory T-cell proﬁles for the identiﬁcation of rejection or to tailor patient’s immunosuppression? Are we ready to
administer regulatory T cells as inductive or adjunctive therapy for kidney transplantation?
1.Introduction
The avoidance of long-term immunosuppression by achiev-
ing immunological tolerance would be the ultimate solution
to improving long-term patient survival and giving kidney
transplant patients a better quality of life. Unfortunately,
owing to its complex immunopathogenesis, true immuno-
logical tolerance to avert alloresponses has been diﬃcult to
achieve. In particular, once the alloresponse is established, it
is extremely diﬃcult to control because of its strong and self-
amplifying eﬀector mechanisms. These obstacles form the
platform of unceasing battles against transplant rejection.
Amongst the mechanisms implicated in the generation
and/or maintenance of immune tolerance, the immunoreg-
ulatory role of regulatory T cells (Tregs) is one of the most
attractive yet elusive one. In the early 1970s, seminal experi-
ments by Gershon and Kondo [1, 2] unveiled the existence of
a population of suppressor T cells, but subsequent failures
to substantiate their theory had led to the demise of their
idea for almost three decades [3, 4]. The interest in the
suppressor T cell resurged in 1995 after Sakaguchi’s work,
which elegantly demonstrated the existence of a subset of
CD4+CD25+ T cells that appeared to be naturally committed
to perform immunoregulation [5]. The expression of the2 Journal of Transplantation
forkhead box transcription repressor factor (Foxp3) was
later found to be characteristic of Tregs [6–8], and their
designation was changed to Foxp3+ Tregs.
Given the vast evidence demonstrating the contribution
of Tregs regulating immune responses in diﬀerent animal
models and clinical situations of autoimmunity and trans-
plantation, great hopes have ﬂourished on the potential use
of Tregs as markers of tolerance, transplant rejection, or
prediction of graft outcomes. Similarly, great eﬀorts have
been put to develop protocols for the use of Tregs as
an immunomodulatory therapy in autoimmunity, allergy,
and transplantation. In this comprehensive review, after a
few notes on Treg biology, we have highlighted the most
important research ﬁndings on the use of Tregs in the
immune diagnosis in kidney transplantation, mainly, based
on histopathological evidence of rejection. We attempt to
draw our conclusions based on the design quality and results
of the available studies. However, with respect to the use of
Tregs as immunotherapy in kidney transplantation, the data
is still scarce.
2. Characterisationof Regulatory T Cells
2.1. Origin and Types of Regulatory T Cells. Tregs consist of
a heterogeneous population of T cells with the ability of
suppressing immune responses. The so-called natural Tregs,
or nTregs, are derived from the thymus [5], while the Tregs
that develop in the periphery during an adaptive immune
responsearereferredtoasinducedTregs,oriTregs.Although
b o t ha r eTc e lls u b s e t swi t hr e g u l a t o ryp r o pe rt i e s ,n T r e gsa n d
iTregs appear to have major diﬀerences with respect to their
developmental pathways, T-cell receptor (TCR) repertoires
[9], as well as activation requirements [10]. It is also likely
thattheyaresegregatedintodiﬀerentcompartmentsfortheir
eﬀector functions.
nTregs develop within the thymic medulla, around
Hassal’s corpuscles, under the inﬂuence of both interleukin-
(IL-)2andtumourgrowthfactor(TGF)β [11,12].Signalling
derived from TCR engagement by major histocompatibil-
ity complex (MHC) molecules loaded with self-peptides
appears to be crucial for their development, as suggested
by the severe depletion of intrathymic Tregs observed upon
disruption of proximal TCR signalling by targeted mutations
[13]. After exiting the thymus into the periphery, nTregs
comprise about 5–10% of the total peripheral T cells [14].
nTregs appear to be a stable population fully and naturally
committed to immunoregulation, and their main role is
thought to contribute to the maintenance of peripheral
tolerance and to prevent the development of autoimmunity.
On the other hand, iTregs develop in the periphery
during an adaptive immune response under the inﬂuence
of diﬀerent cues given by the immune system. In particular,
a milieu rich in IL-2 and TGFβ appears to polarise the
na¨ ıve CD4+ T cells towards the iTreg diﬀerentiation pathway
[15]. Compared to nTregs, iTregs appear to display larger
phenotypic plasticity, with the capacity to transform to
other subtypes of T cells, depending on the prevailing
cytokine milieu. Plausibly, this plastic property of iTregs
may serve a physiological role in the immune system by
ﬁne-tuning T-cell responses according to the requirements
of the immune response. Alternatively, iTregs could be
an inherently unstable population by nature, or simply
represent a self-regulating, transient, anergic state of recently
activated, or overstimulated T cells.
2.2. Demethylation at the Foxp3 Gene as a Marker of Authen-
ticity of Regulatory T Cells. The phenotypic plasticity dis-
played by iTregs, when compared to nTregs, may be owing
to the relatively unstable expression of Foxp3 in the former
population, which in turn could be partially attributable to
the epigenetic diﬀerences in the Foxp3 gene in these two
Treg subsets [16]. Foxp3 gene is demethylated at the so-
called Treg-speciﬁc demethylated region (TSDR) in nTregs,
b u ti sm e t h y l a t e di ni T r e g s[ 17]. Interestingly, demethylation
at the TSDR on the Foxp3 gene has been proposed to be
a hallmark characteristic of authentic Tregs, diﬀerentiating
them from recently activated conventional T cells [17, 18],
which can also express Foxp3 transiently upon activation
[19]. However, unlike nTregs, Foxp3 gene is methylated
at the TSDR in activated T cells. In fact, Bestard et al.
observed that the staining of Foxp3, taking as a surrogate
marker for the presence of Tregs, correlated well with the
detection of demethylation at the TSDR on the Foxp3 gene
on their protocol biopsies [18]. Therefore, they proposed
that the analysis of the methylation status at the Foxp3 gene
TSDR can diﬀerentiate genuine Tregs from recently activated
conventional T cells. The authors concluded that a more
precise delineation of the true phenotype of the inﬁltrating
T cells by methylation status in a kidney transplant biopsy
is likely to better reﬂect the true clinical signiﬁcance and
potential diagnostic and prognostic implications of Tregs.
Further larger studies are required to validate the usefulness
of assessing the methylation status at the TSDR in clinical
transplantation,althoughitispromisingthatthisnoveltech-
nique could potentially add value to the Banﬀ classiﬁcation.
Although the analysis of the methylation status of the
Foxp3 gene at the TSDR appears so far to be the most
speciﬁcmethodforthedetectionofgenuinenTregs,itcannot
distinguish iTregs from recently activated non-Tregs, as both
populations appear to have methylated Foxp3 gene at the
TSDR. The diﬃculty of accurately separating these two T-
cell populations with completely diﬀerent function may have
had led to erroneous conclusions drawn in many previous
studies. This molecular predicament may also explain why in
some studies the detection of Tregs and/or Foxp3 transcripts
did not correlate with outcomes (see below), as it is possible
that the Foxp3-expressing T cells were not authentic Tregs
but simply activated conventional T cells.
2.3. Phenotype of Regulatory T Cells. One of the diﬃculties
in the detection and/or isolation of Tregs in peripheral blood
is the absence of a speciﬁc surface marker. Many surface
markerssuchasCD25,CD39,CD73,CD103,CD134,CD152
(cytotoxic T lymphocyte antigen (CTLA)-4), CD196, and
CD357 have been identiﬁed on Tregs [20–26]; however, they
are not speciﬁc for Tregs as these markers can be expressedJournal of Transplantation 3
on activated eﬀector T cells (Teﬀs) or other cell populations.
Although the expression of Foxp3 appears to be the most
reliable signature of both nTregs and iTregs [11], it is not
expressed on the cell membrane, which precludes its use as a
selection markerforisolation. Nonetheless, Foxp3 appearsto
be pivotal for the development of Treg phenotype and their
function [6–8], hence, the detection of Foxp3 expression or
transcripts is employed by some investigators as a surrogate
marker for the presence or the involvement of Tregs in
immunoregulation (see below). Sakaguchi’s team has sug-
gestedthatthediﬀerentialexpressionofcertainsurface,cyto-
plasmic and nuclear markers, in particular CD45RA, CD25,
CD152, and Foxp3, can help to diﬀerentiate resting Tregs
(CD45RA+CD25+CD152loFoxp3lo) from the highly sup-
pressive activated Tregs (CD45RA−CD25hiCD152hiFoxp3hi)
[27]. However, for a more precise delineation, assessment of
their proliferative state, production of inhibitory cytokines,
in vitro suppressive capacity, and analysis of Foxp3 gene
methylation appear to be also important.
2.4. Suppressive Mechanisms Deployed by Regulatory T Cells.
Tregs, similar to conventional T cells, appear to require
antigen-speciﬁc TCR ligation for their activation, however
theirsuppressivecapacitiesappeartobenon-antigen-speciﬁc
[28]. They have been shown to be able to inhibit T helper
(Th)1 cells, Th2 cells, Th17 cells, dendritic cells (DCs),
natural killer cells, B cells, and cytotoxic T lymphocytes
(CTLs) [28–31], all of which are known eﬀectors of allograft
damage. Mechanistically, in several experimental models,
theywerefoundtoinhibitseveralcomponentsofanimmune
response, including IL-2 transcription in Teﬀs, interferon
(IFN)γ secretion by CTLs as well as DC function [28,
32, 33]. In addition, they appeared to be equipped with
suppressive cytokines (such as TGFβ) on their surface for
immunosuppression, have the capacities to induce apoptosis
of Teﬀs, and to degrade inﬂammatory extracellular adeno-
sine triphosphate (ATP) [28, 31, 34, 35].
Like conventional Teﬀs, Tregs also diﬀerentiate into
eﬀector/memory cells upon antigen-contact [31]. Na¨ ıve-
type Tregs have been shown to express CD62L and CD197
(chemokine receptor CCR7) [36], which can help them to
home primarily to secondary lymphoid organs, where they
could potentially modulate the interaction of na¨ ıve T cells
with antigen-presenting cells (APCs) to prevent excessive
stimulation of T cells, or to control their diﬀerentiation.
In contrast to na¨ ıve-type Tregs, eﬀector/memory-like Tregs
(TREM) appear to suppress inﬂammation directly inside
the tissue, including the kidney allograft. The TREM cells
seem to be the natural counterplayers of Th17 cells, an
eﬀector/memory subset involved in the propagation of
proinﬂammatory responses. Remarkably, both the TREM
and the Th17 cells share the expression of the chemokine
receptorCD196,suggestingcolocalisationinsitesofimmune
inﬂammation. Recent studies propose that ATP catabolising
enzymes such as CD39 and CD73 expressed on the surface
of TREM cells may play a major role in this process [23, 24].
We and other authors have proposed that the expression of
CD39 together with other surface markers helps to facilitate
the detection of Tregs, particularly the TREM subset. CD39,
being an ATPase, removes extracellular ATP released during
tissue injury, which is known to be an important mediator of
inﬂammationactingonpurinergicreceptorsandtheninduc-
ing the secretion of IL-1 [37]. Therefore, ATP catabolism by
the TREM subset through CD39 during transplant rejection
could be one of the key mechanisms employed by Tregs to
control progressive injury [38]. Since the TREM cells have
been suggested to manifest their regulatory functions after
inﬁltrating the tissues, it might be more relevant to locate
their presence in the kidney transplant T cell inﬁltrates
rather than the general identiﬁcation of na¨ ıve Tregs or
Foxp3transcripts.Ourgroupsareatpresentinvestigatingthe
potentialimmunodiagnosticandimmunepredictivevalueof
the detection of TREM cells in clinical kidney transplantation.
3. Role of Regulatory T Cells inTransplantation
It is now a widely held belief that Tregs have a key role
in the immune regulation of transplant rejection. There is
a vast amount of data in the literature demonstrating the
importance of Tregs in several animal models of transplan-
tation [39–42]. However, most of these are models of skin,
pancreatic islets, or heart transplantation. Data from the
latter model might resemble more accurately the transplant
kidney setting as both kidneys and hearts are vascularised
organs. Interestingly, in many models of transplantation,
functional Tregs were detected within tolerated grafts [43,
44]. For example, in an elegant murine model of skin graft
tolerance [43], the intragraft Tregs were able to transfer the
tolerant state to other animals if the tolerated skin was re-
transplanted to na¨ ıve animals. This suggested that Tregs can
actively operate their immunoregulation properties not only
in the secondary lymphoid tissues, but also inside the graft
directly where the alloantigens and the immunoaggressive
cells (i.e., Th1 cells, Th17 cells, and CTLs) interact. Plausibly,
Tregs could be recruited and activated inside the graft, where
they play an important modulatory role in silencing the
eﬀector destructive responses, by arresting the proliferation
of Teﬀs, as well as “prohibiting” their cytokine production
capacity, rendering them anergic, as well as inducing their
apoptosis, so as to prevent excessive inﬂammation and col-
lateral damage. It has been postulated that the most crucial
factor to the outcome of an allograft is the balance between
the ratio of Teﬀs versus Tregs, either in numbers or in overall
functional predominance. However, the factors that underlie
the balance between these antagonistic responses are still
poorly understood.
4. Regulatory T Cellsand ImmuneTolerance in
ClinicalKidney Transplantation
4.1. Regulatory T Cells as Markers of “Operational” Tolerance
in Kidney Transplantation. The observation of a small subset
of kidney transplant patients that spontaneously accepted
their grafts in the absence of immunosuppression, the so-
called“operationaltolerance”hasgivenushopeinoursearch
for the “holy-grail” in transplantation tolerance. Whether4 Journal of Transplantation
Tregs are part of that “holy-grail” is still unknown and
continues to puzzle us.
In a cross-sectional analysis comparing the numbers of
circulating Tregs among normal subjects, patients undergo-
ing chronic rejection, and patients tolerant to their kidney
grafts [45], the authors found that the patients undergoing
chronic rejection had lower levels of CD4+CD25+ Tregs and
Foxp3 transcripts, and higher numbers of CD4+ Tc e l l s
with cytotoxic phenotype than the other two groups. In
addition, the patients with tolerated kidney grafts displayed
similar number of blood Foxp3+ Tregs when compared
to healthy subjects. From their observations, it cannot be
concluded that the Tregs were responsible for the diﬀerent
clinical outcomes, and perhaps the diﬀerent numbers in
Tregs between the patients chronically rejecting their grafts
and the tolerant ones could simply be related to the pres-
ence, absence, or type of immunosuppression. Nevertheless,
the existence of kidney transplant patients spontaneously
tolerating their grafts has sustained a series of enthusiastic
investigations searching for clues to decipher the secrets of
transplantation tolerance. A comparative assessment of the
relative function and phenotype of the circulating Tregs in
those groups of patients would have been desirable, but it
was not performed. Moreover, a phenotypic characterisation
of the T cell inﬁltrates in biopsies of the tolerated kidneys in
these patients may be more informative, though not sensible
from the ethical point of view as explained by the authors.
By the use of microarray analysis, the same group
subsequently demonstrated the expression of a particular set
of 49 genes in the tolerant patients not expressed in other
patients [46], including Foxp3 and genes regulated by TGFβ,
which is an important cytokine for Treg development and
function. They proposed that these genes could be potential
biomarkers for tolerance achievement in kidney transplan-
tation. Although their results require further validation,
this has nevertheless fueled more interest in the pursuit of
transplantation tolerance.
4.2. Induction of “Operational” Tolerance in Clinical Kidney
Transplantation. Research performed under the auspices
of the immune tolerance network has revealed long-term
donor-speciﬁc unresponsiveness up to 3 years of followup in
a small case series of 5 patients that underwent combined
kidney and bone marrow transplantation (BMT). These
patients were subjected to an immunoablative protocol
consisting of anti-CD2 monoclonal antibody (mAb) and
cyclophosphamide with or without rituximab and thymic
irradiation to facilitate engraftment and attempting to
induce “operational” kidney transplant tolerance [47]. Inter-
estingly, the tolerant patients displayed an increment in Treg
numbers during the lymphopenic period in early stages
posttransplantation and in vitro assessment of allorespon-
siveness demonstrated Treg-mediated immunoregulation.
This unresponsiveness state persisted beyond 18 months
posttransplantation,butnosigniﬁcantTreg-dependenteﬀect
was detected afterwards, and the authors concluded that
clonal anergy or deletion was the most likely impli-
cated mechanisms in later stages posttransplantation. This
protocol appeared to be safe, as no serious opportunistic
infections were reported despite prolonged lymphopaenia.
However, one patient required treatment for acute antibody-
mediated rejection (AMR).
Scholars and researchers of immune tolerance have long-
realised that resetting the immune system through systemic
and thymic immunoablation followed by BMT has been
a successful model for the induction of tolerance in vivo
in diﬀerent experimental models, and this small case series
indeed boosts our conﬁdence in such protocols for clinical
application. However, wider experience on the safety of
immunoablation and combined kidney and BMT as therapy
for patients with kidney failure, without haematological
malignancies warranting BMT, are still required before wide
applicability of such protocols can be recommended to the
vast population of kidney failure patients.
5.Regulatory TCellsasImmunodiagnostic
Tools inKidney Transplantation
The role of circulating Tregs in the inhibition of allospeciﬁc
indirect pathway was ﬁrst reported in 2003 in kidney trans-
plant patients with stable kidney function [48]. It was then
hoped that the presence of Tregs or the detection of Foxp3
transcripts in blood, ﬂuid, or tissues, in particular inside the
kidney graft, could be reﬂective of immunoregulation and be
correlated with graft outcomes. In the following subsections,
we describe the studies assessing the role of the detection of
Tregs in the immunodiagnosis of kidney transplant rejection
and the prediction of graft outcomes. Table 1 compiles the
studies supporting a role of Treg and/or Foxp3 analysis
for the immunodiagnosis of transplant rejection or the
prediction of graft outcomes in kidney transplantation,
while Table 2 summarises the studies reporting conﬂicting
results or questioning the utility of Tregs and Foxp3 as
immunodiagnostic and immunopredictive tools for kidney
transplantation. We conclude this section by attempting
to reconcile the contradictory results and suggest some
conclusions based on the most compelling evidence.
5.1. Studies Associating Regulatory T Cells with the Diagnosis
ofKidneyTransplantRejectionandwithGoodGraftOutcomes.
Attempting to ﬁnd a protective value of the detection
of Foxp3 transcripts, a prospective study in 36 kidney
transplant patients undergoing acute rejection reported
signiﬁcantly higher levels of Foxp3 transcripts in spun
urinarycells,associatingthepresenceofFoxp3withrejection
[49]; contrary to the general expectations that expression
of Foxp3, being a marker of Tregs, should be lower in
rejection. Nonetheless, high Foxp3 transcripts levels were
signiﬁcantly associated, though weakly, with better serum
creatinine levels measured during the episode of rejection.
In addition, patients with both rejection and higher levels
of urinary Foxp3 transcripts had better responsiveness to
steroid treatment than the patients with lower levels, and
they also had signiﬁcantly lower risk for graft failure. These
authors went on to show that the measurement of Foxp3
transcripts appeared to correlate better with outcomes thanJournal of Transplantation 5
Table 1: Studies supporting the association of regulatory T cells with diagnosis of kidney rejection and graft outcomes prediction.
Reference Study design Patient
characteristics
Immunodiagnostic
ﬁndings Graft outcomes Conclusions/additional
comments
Muthukumar
et al. [49] Prospective
83 total pts (36pts
with graft
dysfunction and
BPAR)
Increased Foxp3
transcripts in urinary
cells in pts with BPAR
Better kidney function
and lower risk of graft
failure in pts with BPAR
and higher levels of
Foxp3 transcripts
Demonstration of potential
role of the measurement of
Foxp3 transcripts for
diagnosis of rejection and
outcomes prediction
Wang et al. [50]P r o s p e c t i v e
10 living-donor
transplant pts with
BPAR
Increased Foxp3
transcripts in
peripheral blood
associated with BPAR
Measurement of Foxp3
transcripts in peripheral
blood may aid the
immunodiagnosis of
rejection in living-donor
transplantation/sample size
too small to be conclusive,
but ﬁndings are
encouraging
Martin et al.
[51] Retrospective 11 of 17pts with
acute BPAR
Patients with Foxp3+
inﬁltrates had better
kidney function and
lower rates of graft loss
at 1-year
posttransplantation
Tregs inﬁltration in graft
might correlate with
favourable graft
outcomes/sample size too
small to be conclusive and
some patients who lost
their graft had evidence of
humoral rejection
Aquino-Dias
et al. [52] Prospective
35pts with DGF
(total 48 biopsies:
20 with BPAR and
28 with ATN)
Increased Foxp3
transcripts in kidney
tissue, peripheral
blood and urinary
cells correlated with
BPAR when
compared to ATN
Measurement of Foxp3
transcripts may aid the
early identiﬁcation of
rejection for pts with DGF
Grimbert et al.
[53]
Cross-
sectional
26pts with kidney
dysfunction (15pts
with borderline
rejection and 11
with type IA acute
TCMR)
Higher ratios for the
transcripts of
Foxp3/granzyme B
were found in pts
with borderline
rejection in
comparision with pts
with type IA acute
TCMR
Tregs could play a
protective role
ameliorating inﬂammation
and preventing the
progression to frank
rejection
Mansour et al.
[54] Retrospective
46pts with
borderline
rejection
Increased Foxp3
transcripts in pts with
stable creatinine
compared to pts who
p r o g r e s s e dt oB P A R
No diﬀerence found in
kidney function at 2
years in both pts with
treated BPAR and pts
with stable creatinine
Measurement of Foxp3
transcripts may have
prognostic value in
borderline rejection
Bestard et al.
[56] Retrospective
37pts with SCR
from 170 protocol
biopsies
Fewer Tregs were
observed in pts on
ciclosporin
The presence of Treg
inﬁltrates correlated
with better graft
function at 2- and
3-years
posttransplantation
Presence of Tregs
inﬁltration could prevent
the progression from SCR
to clinical rejection
Bestard et al.
[18] Retrospective 37pts with SCR
Number of
inﬁltrating Tregs in
pts with SCR
correlated with Foxp3
demethylation at the
Treg-speciﬁc
demethylation region
The presence of Treg
inﬁltrates correlated
with better graft
function and survival up
to 5-year
posttransplantation
Presence of Tregs
inﬁltration in rejection
associates with better graft
outcomes/the Banﬀ
classiﬁcation alone is
insuﬃcient for
immunodiagnosis and
prognostication purposes6 Journal of Transplantation
Table 1: Continued.
Reference Study design Patient
characteristics
Immunodiagnostic
ﬁndings Graft outcomes Conclusions/additional
comments
Xu et al. [57]R e t r o s p e c t i v e
125pts with
protocol biopsies
with presence of T
cell inﬁltrates (14
with SCR, 32 with
borderline
rejection, 79 with
no rejection)
Higher ratios for the
transcripts of
Foxp3/granzyme B
correlated with lower
risk for rejection
Higher ratios for the
transcripts of
Foxp3/granzyme B
predicted better kidney
function and graft
survival up to 5-year
posttransplantation
Tregs could play a
protective role reducing
rejection risk and
improving graft
outcomes/unable to
provide conclusions for pts
without T cell inﬁltrates
Zuber et al. [58]R e t r o s p e c t i v e
67pts (34 with
acute TCMR, 33
with chronic
TCMR)
Higher number and
ratio of Tregs over
total T cells were
observed in patients
with chronic rejection
than with acute
rejection
T h eg r e a t e rt h eT r e g
inﬁltrate in inﬂamed
scarred areas, the better
the graft survival
Tregs might be protective
in chronic rejection
ATN: acute tubular necrosis; BPAR: biopsy proven acute rejection; DGF: delayed graft function; pts: patients; SCR: subclinical rejection; TCMR: T-cell-
mediated rejection. Blank area: not assessed.
the histological grade of the Banﬀ classiﬁcation. These
ﬁndings seem to imply that the greater the number of Tregs
recruited in response to the inﬂammation of transplant
rejection, the better the chances to overcome it. Moreover,
these interesting results suggested a potential role of the
measurement of Foxp3 transcripts in the immune diagnosis
of kidney transplant patients, and a beneﬁcial link between
the presence of Tregs and better kidney transplant outcomes
following a rejection episode.
A more recent but small prospective study further sup-
ported the relationship of Foxp3 transcripts with rejection
[50]. These authors found that Foxp3 transcript levels
increased in the peripheral blood of 10 recipients of living-
donor kidney transplants undergoing acute rejection in
comparison with stable patients.
Anothersmallretrospectivestudyin17kidneytransplant
patients claimed that graft inﬁltration with Tregs might
c o r r e l a t ew i t hf a v o u r a b l eg r a f to u t c o m e s[ 51]. The patients
with no Foxp3+ T cells within their inﬁltrates (n = 6) had a
nonsigniﬁcant trend towards higher serum creatinine levels
and a signiﬁcantly higher rate (50%) of graft loss within the
ﬁrstyearaftertransplantation, comparedtothepatientswith
Foxp3+ T cell inﬁltrates. Although encouraging, the sample
size was too small to be conclusive. Furthermore, 2 of the
3 patients who lost their graft had positive staining for the
complement derivative C4d, which is a surrogate marker for
antibody-mediated injury, indicating that graft loss could
have been due to AMR and not purely due to the lack of
Tregs.
5.2. Regulatory T Cells Analysis in Delayed Graft Function. In
another prospective study of 35 kidney transplant patients
with delayed graft function (DGF), a similar conclusion
was drawn on the diagnostic potential of Foxp3 expression
for acute rejection [52]. The authors reported that the
expression of genes associated with CTLs, which are key
p l a y e r si nr e j e c t i o n ,a sw e l la sF o x p 3e x p r e s s i o n ,a sa
marker of immunoregulation mediated by Tregs, in kidney
biopsy tissue, peripheral blood cells, and urinary cells,
was signiﬁcantly higher in patients with acute rejection
when compared with those with acute tubular necrosis.
Remarkably, the correlation of Foxp3 transcripts with acute
rejectionwasthestrongestamongallthebiomarkersstudied,
suggesting a utility of reverse-transcriptase polymerase chain
reaction for Foxp3 for the early diagnosis of acute rejection
in patients with DGF [52].
5.3.RegulatoryTCellsRoleinBorderlineRejection. Inacross-
sectional study of biopsies of 15 kidney transplant patients
with clinical dysfunction and borderline rejection, higher
ratios of transcripts for Foxp3 when compared to transcripts
for granzyme B, a surrogate marker for CTLs, were found,
in comparison with patients with type IA acute T-cell-
mediated rejection (TCMR) [53]. The same authors, in
another retrospective study of 46 kidney transplant biopsies
with borderline rejection, found that Foxp3 transcripts levels
were signiﬁcantly higher in the 25 patients with stable serum
creatinine levels when compared to the 21 patients who
progressed to biopsy proven acute rejection (BPAR) in a
repeat biopsy at 40 days [54]. The authors did not observe
signiﬁcant diﬀerence between the two groups in the expres-
sion of granzyme B, IFNγ, IL-23, or RORγt, considered
markers of CTLs and Th17 cells. All the patients with BPAR
in the repeat biopsy received antirejection treatment, and no
diﬀerence in kidney function at 2 years was found between
this group and the patients who did not progress to BPAR.
Altogether, their ﬁndings suggested a protective role of
Tregs in ameliorating transplant inﬂammation and, perhaps,
“retarding the progression” in the Banﬀ classiﬁcation. In
addition, their results suggested that the Foxp3 levels in
patients with borderline rejection can have a prognostic
value, and low levels could warrant a follow-up biopsy or the
initiation of antirejection therapy.Journal of Transplantation 7
Table 2: Studies with conﬂicting results regarding the association of regulatory T cells with kidney rejection and graft outcomes prediction.
Reference Study design Patient characteristics Immunodiagnostic
ﬁndings Graft outcomes Conclusions/additional
comments
Bunnag et al.
[59] Retrospective 77pts
(42 with BPAR)
Higher levels of
Foxp3 transcripts
associated with
acute TCMR and
AMR in the
univariate but not
in the multivariate
analysis
No relationship was
found between Foxp3
expression and graft
outcomes. Only C4d
positivity and
inﬂammation
biomarkers related to
outcomes in their
multivariate analysis
Foxp3 expression accompanies
the inﬂammatory process rather
than being a marker of
alloimmunity
Veronese
et al. [60] Retrospective 73pts
(59 with BPAR)
High expression of
Foxp3 was
associated with
acute TCMR but
not with AMR
2-year graft survival
was worse in pts with
BPAR and higher
Fopx3 expression
No prognostic value was given to
the analysis of Foxp3 expression
in patients with
BPAR/diﬀerentiation of
authentic Tregs from recently
activated Foxp3+ T cells could
have been useful to understand
their results
Taﬂin et al.
[61] Retrospective
24 biopsies with graft
dysfunction (12 with
BPAR and 12 with
borderline rejection)
and 16 protocol biopsies
at 1-year
posttransplantation
Treg inﬁltrates
were higher in
borderline
rejection and SCR
compared to
patients with acute
TCMR
Tregs may have a beneﬁcial role
against overt rejection. The
authors questioned the
diagnostic value of Treg
identiﬁcation for the diagnosis of
rejection
Batsford et al.
[62] Retrospective
32 biopsies taken on
23pts (16 biopsies with
BPAR)
No relation of
Foxp3+ Tregs
detection with
acute rejection
No prognostic value
of the measurement
of Tregs at one-year
posttransplantation
Measurement of Tregs has no
diagnostic nor prognostic
value/only Banﬀ type 1 acute
TCMR was included, and
biopsies with higher grades of
rejection and likely larger
inﬁltrates were excluded, which
likely biased their results
Kollins et al.
[63] Prospective
55pts (29 protocol
biopsies with no
rejection, and 26
indication biopsies with
BPAR)
No association
between numbers
of inﬁltrating Tregs
and diagnosis of
rejection
No correlation
between Treg
inﬁltrates and kidney
function at 1- and
2-year
posttransplantation
Measurement of Tregs has no
diagnostic nor prognostic
value/in the protocol biopsy
group, biopsies devoid of
signiﬁcant inﬂammatory
inﬁltrate and those with inﬁltrate
not diagnostic of acute rejection
were excluded, which likely
biased their results
AMR: antibody-mediated rejection; BPAR: biopsy proven acute rejection; pts: patients; TCMR: T-cell-mediated rejection. Blank area: not assessed.
5.4. Regulatory T Cells Utility in Protocol Biopsies and
Subclinical Rejection. In another study, a state of hypore-
sponsiveness related to peripheral and tissue inﬁltrating
Tregswasobservedinkidneytransplantpatients,particularly
with concurrent anti-thymocyte globulin (ATG) induction
and sirolimus-based immunosuppressive regimen [55], both
known to have positive eﬀects on Tregs (see below). These
authors subsequently published interesting ﬁndings on a
retrospective study on protocol biopsies at 6 months post-
transplantation in 37 kidney transplant patients [56]. The
presence of Tregs in the inﬁltrates as well as the proportion
of Tregs over the total T cell inﬁltrate positively correlated
with better graft function at 2 or 3 years posttransplantation,
regardless of the use of sirolimus, which is known to have
positive eﬀects on Tregs. They also proposed that dominant
Treg inﬁltration could be the underlying factor to prevent
progression from subclinical rejection (SCR) to clinical
rejection.
In a more recent retrospective study of 37 patients
diagnosed with SCR in 6-month protocol biopsies by the
same group, they corroborated that the presence of Tregs
in patients with SCR associates with better kidney function
and graft survival up to 5 years posttransplantation, when
compared to patients with SCR but with no inﬁltrating
Tregs [18].ThisemphasisesthatusingtheBanﬀclassiﬁcation
alone may be insuﬃcient for prognostication purposes,8 Journal of Transplantation
and additional characterisation of the inﬁltrate in kidney
transplant biopsies may have added importance. Since the
decision to treat patients with SCR is often a therapeutic
dilemma, it might be more sensible to treat rejection or to
enhancetheimmunosuppressionforthosepatientswithSCR
devoid of Treg inﬁltration.
In another retrospective study of selected 125 protocol
biopsies with lymphocyte inﬁltrates, 14 of them with SCR,
32 of them with borderline rejection, and 79 not classiﬁed
as rejection, the authors found that the ratio of Foxp3
to granzyme B transcripts was able to predict risk for
rejection within one year of biopsy and observed better
kidney function and graft survival up to 5 years of followup
[57]. Extra 45 protocol biopsies not showing lymphocyte
inﬁltration were not factored in their prediction analysis,
but 13% of this subset developed acute rejection within 3
years of followup. Overall their results suggested that when
a T-cell inﬁltrate is present in a protocol biopsy the greater
the Treg inﬁltrate over the Teﬀ inﬁltrate, the greater the
likelihood for better kidney graft outcomes; however, it is
diﬃcult to lead to conclusions regarding the utility of the
analysis of the Treg/Teﬀ ratio in the absence of lymphocytic
inﬁltrates.
5.5.RegulatoryTCellsinChronicKidneyTransplantRejection.
In a retrospective study in 67 biopsies performed due to
rising serum creatinine levels, 34 of them showing acute
TCMR and 33 displaying chronic TCMR, the ratio of Tregs
over total T cells and the absolute number of Tregs was
greater in the biopsies with chronic inﬁltrates in scarred
areas than in patients with acute TCMR [58]. In addition,
greater numbers of Tregs in inﬂamed scarred areas appeared
to correlate with better graft survival [58]. This study further
supports the assessment of total inﬂammation scores in
kidney transplant biopsies and, importantly, suggests that a
characterisation of the phenotype of the T cell inﬁltrates is
required to give a more precise prognostic value to a biopsy
showing chronic TCMR.
5.6.ConﬂictingReportsontheAssociationofRegulatoryTCells
with Acute Kidney Transplant Rejection and Graft Outcomes
Prediction. All the aforementioned studies support a poten-
tial clinical utility of Foxp3 expression in the identiﬁcation
of acute rejection and/or the prediction of better graft
outcomes. However, contradictory results have also been
reported by some other groups.
Despite an apparent association with the diagnosis of
rejection, Foxp3 expression did not associate with kidney
graft outcomes in a retrospective study of 83 biopsies, 42 of
them with BPAR, taken from 77 kidney transplant patients
[59].Intheirunivariateanalysis,theauthorsobservedhigher
expression levels of Foxp3 in patients with acute TCMR and
AMR, as well as a correlation with more severe interstitial
inﬂammation, tubulitis, C4d deposition, tubular atrophy,
and interstitial ﬁbrosis, but there was no relationship with
glomerulitis or arteritis, nor chronic glomerulopathy or
vasculopathy. However, in their multivariate analysis only
C4d positivity and biomarkers of inﬂammation were asso-
ciated with graft outcomes. Thus, the authors concluded that
Foxp3 expression was not a marker of alloimmunity but
rather of any inﬂammatory process accompanying acute or
chronic rejection [59]. Nevertheless, more detailed studies
with a larger sample size per subgroup were suggested by the
researchers to conﬁrm these data.
Similar discouraging observations were reported in a
relatively large retrospective series on biopsies from 73
kidney transplant patients, 59 of them presenting with BPAR
[60]. These authors showed that high expression of Foxp3
was closely associated with acute TCMR, but not with AMR
or calcineurin inhibitor (CNI) nephrotoxicity. However, the
2-year graft survival in the kidney transplant patients with
acute rejection and high expression of Foxp3 was worse than
in those with rejection and low levels of Foxp3. In addition,
the authors found no association between the Foxp3 expres-
sionlevelandtheserumcreatininelevelatthetimeofbiopsy.
Intheirimmunostaining,theyobservedthatmostofthecells
expressing Foxp3 were CD4+ T cells, while few of them were
CD8+. One simplistic explanation of the negative association
of Foxp3 expression with graft outcomes in this study is that
a high observed number of recruited Tregs in the transplant
kidney may be a part of an intense inﬂammatory inﬁltrate
of alloreactive Teﬀs without having the actual Treg/Teﬀ ratio
favouring the immunoregulatory branch of the immune
system. Thus, a high number of Teﬀsw o u l db em o r e
diﬃculttosuppressirrespectiveofalargeaccompanyingTreg
inﬁltrate. Alternatively, the Tregs recruited during a rejection
episode could be dysfunctional, so their presence might not
correlate with the degree of inﬂammation or the outcome
of the immune activation. Another possibility is that the use
of Foxp3 expression as a surrogate marker for Treg presence
or function could lead to an overestimation of the actual
amount of Treg-mediated immunosuppression, as it is well
knowninhumansFoxp3canbeexpressedtransientlybyTeﬀs
during their activation [19].
Another retrospective study found that the proportion of
Tregs in CD4+ T inﬁltrates was higher in borderline rejection
and SCR when compared with T-cell-mediated rejection,
while the proportion of Teﬀs was equivalent in both situa-
tions [61]. Their results indeed suggested a protective role of
the presence of Tregs against overt rejection. However, they
question the value of identifying Tregs for the diagnosis of
rejection, as their presence was not associated with a worse
histopathological diagnosis.
Other recently published studies also found no corre-
lation between Foxp3+ Treg inﬁltrate and graft function.
However, their results must be interpreted with caution. One
retrospective study on 32 biopsies taken from 23 kidney
transplant patients claimed no diagnostic value for acute
rejection nor a prognostic value at 1 year [62]. However,
the authors included only patients with Banﬀ t y p eIa c u t e
TCMR, excluding patients with higher grades of rejection
who are likely to have higher T-cell inﬁltrates and likely
diﬀerent outcomes. Another recent prospective study on
55 kidney transplant patients also showed no correlation
betweentheFoxp3+ Treginﬁltratesandkidneyfunctionat12
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obtained from protocol biopsies with the ones obtained
in patients with BPAR [63]. However, in their protocol
biopsies group, patients with biopsies devoid of signiﬁcant
inﬂammatory inﬁltrate and those not diagnostic of acute
rejection were all excluded, which could have biased their
results and conclusions.
5.7. Are We Ready Then for the Use of Regulatory T Cells for
the Diagnosis of Kidney Transplant Rejection and Prediction
of Graft Outcomes? In all these studies, the true signiﬁcance
of the presence of Tregs or upregulated Foxp3 in acute
rejection episodes could not be exactly ascertained. Con-
ceivably, it could represent a marker of immunoregulation,
or, alternatively, simply reﬂect the massive T-cell activation
during a rejection episode since Foxp3 expression is not
only conﬁned to Tregs but also known to be upregulated
in activated conventional T cells as well [19]. However, the
relation of Tregs with better outcomes in some of these
studies supports the former hypothesis, which appears to
concur with the animal data demonstrating the presence of
functionally active Tregs inside tolerated grafts [43].
Atleastinpart,thesurprisinglyweakcorrelationbetween
a positive outcome and the presence of Tregs may be
due to the negative eﬀects of immunosuppressive drugs
in Treg development and function. Indeed, some reports
have showed that a few immunosuppressive drugs like
ciclosporin A [64] and basiliximab [65, 66]a p p e a rt oh a v e
an e g a t i v ee ﬀect on Tregs in renal transplant recipients,
while other drugs favour the induction and maintenance of
Tregs, particularly the inhibitors of the mammalian target
of rapamycin [64, 67]a n dA T G[ 68–70]. Despite knowledge
of the speciﬁc eﬀects of immunosuppression on Tregs is
of crucial importance, a more detailed description of these
eﬀects is beyond the scope of this paper, and interested
readers may refer to the relevant section in our previous
publication [38].
It is also worth mentioning that immunosuppressive
drugs can lead to a reduction in total T-cell numbers
and depending on speciﬁc cell-type sensitivity to particu-
lar drugs, their eﬀects will also skew Treg representation
within the T-cell populations in the circulation. Therefore,
it appears that analysing intragraft Teﬀsa n dT r e g sm a y
therefore reﬂect more accurately the state of the immune
system during a rejection episode than the analysis of
these cells in peripheral blood. Moreover, it is possible that
many of the intercellular interactions or soluble signals
tuning the balance from rejection towards alloprotection
might be occurring within the draining lymph nodes [71].
However, obtaining draining lymphatic tissue for research
or diagnostic purposes in clinical kidney transplantation
would be technically challenging and perhaps not sensible
from the ethical point of view. Therefore, we can only make
extrapolations based on a reductionist model. On balance, it
is plausible that the more stable nTregs exert their regulatory
action directly on APCs or the activated T cells inside
secondarily lymphoid tissue, whilst their less stable partners,
the iTregs, act on tissue-inﬁltrating Teﬀs instead.
Though there are conﬂicting results on the utility of
Tregs for the immune diagnosis and prediction of outcomes
in clinical transplantation, we believe that all the evidence
presented here on balance favours a positive role of Tregs in
the diagnosis of kidney transplant rejection and prediction
of graft outcomes. However, at present, neither general nor
deﬁnitive recommendations can be drawn regarding the
detectionofTregsforthediagnosisofacutekidneytransplant
rejection for modiﬁcation of immunosuppressive regimens
or outcomes prediction. Despite this, it is possible that the
immunostaining for Foxp3+ Tregs in patients with SCR on
protocol biopsies or in patients with DGF might ultimately
be useful to identify patients with high risk of rejection,
who might beneﬁt from closer follow up or a more tailored
immunosuppressive regimen.
6. Regulatory T Cellsas Immunomodulatory
Therapy inClinicalKidney Transplantation
6.1. Paving the Path. There is also ample evidence in
the literature demonstrating the potential use of Tregs as
therapeutic tools [5]. The seed of hope for Tregs to be
used as immunotherapy germinated from adoptive transfer
experiments in mice, where the administration of T cells
with regulatory properties was shown to prolong the survival
of allogeneic grafts [72, 73]. Interestingly, this transplant
tolerance can be also “infectiously” transferred to na¨ ıve
animals by the administration of Foxp3+ Tregs from tolerant
animals, showing a therapeutic potential [74]. In addition,
the transduction of CD4+CD25− T cells with the Foxp3
gene, in other words, na¨ ıve T cells forcefully converted
into iTregs, were associated with the prolongation of the
survival of skin allografts in mice [75]. While in principle
the presence of Tregs is required to achieve tolerance,
functional state and subset composition may be more
crucial for long-term graft survival. In a murine adoptive
transfer model, it was observed that Tregs from CD39-
deﬁcient mice were not eﬃcient in preventing rejection of
allogeneic skin grafts in comparison with the administration
of wild-type Tregs expressing CD39 [23]. In humans, CD39
is speciﬁcally expressed on the TREM subset [24], which
suggests a potential role of this subset in an allogeneic
transplantation setting and a potential use of the expression
ofCD39onTregsaspartoftheirarmamentariumtoperform
immunoregulation. However, very scarce data exist on the
administration of Tregs for the induction of immunosup-
pression, prevention, or treatment of rejection, especially
for solid organ transplantation, in comparison with the
advances achieved for haematopoietic stem cell transplanta-
tion (HSCT) and the prevention of graft-versus-host disease
[76–78] .I tm a yb em o r ed i ﬃcult to manipulate a complex
alloresponse induced by structurally intricate organs like the
kidney,inwhichmanycelltypesandmorevariedarmsofthe
immune response could be implicated. In addition, unlike
HSCT, solid organ transplantation does not beneﬁt from the
resettingoftheimmunesystemandthemicrochimerismthat
usually follow HSCT. Nonetheless, the growing amount of10 Journal of Transplantation
dataandprotocolsusedforHSCTisservingasscaﬀoldingfor
the construction of protocols in solid organ transplantation.
6.2. Overcoming the Challenges. Besides the partially under-
stood immunological barriers, there are quite a few technical
barriers as well as clinical and ethical concerns that have
made implementation of Treg-based therapy an uphill task.
Nevertheless, major progress has been made that could give
Treg infusions a place in clinical transplantation in the
near future. It has been diﬃcult to enrich this relatively
rare population of T cells from peripheral blood, from
which a deﬁnitive surface selection marker has been lacking.
Although CD4 and CD25 continue to be useful for the
identiﬁcation of Tregs, neither marker is unique to human
Tregs in contrast to mice. Intermediate amounts of CD25
are expressed by conventional Teﬀs and the TREM subset,
and, furthermore, the positive selection of Tregs using anti-
CD25 mAbs could alter the activation status of the cells.
Improved selectivity could be reached by combining CD25
with CD127, a marker found to be absent on most Tregs [79,
80]. A recently described puriﬁcation method of Tregs even
oﬀers to obtain “untouched” Tregs [81]. This puriﬁcation
method, which involves the removal of CD49d+/CD127+
cells, containing much of the unwanted CD25+ Teﬀs, leads
to enrichment of a pure population of Tregs, which are
CD49d−/CD127low.
Tregs also appear to be diﬃcult to expand in culture and
to maintain for prolonged periods of time, not to mention
their very restrictive culture needs. Nevertheless, several
protocols have been developed for large scale expansion of
Tregs. For instance, high doses of IL-2 plus anti-CD3/anti-
CD28 mAbs or the use of DCs together with anti-CD3 mAbs
have been used for polyclonal expansion of Tregs isolated
from mouse and human. Not only that the Tregs expanded
under these conditions retained their suppressive activity,
but also their potency appeared to increase compared to
freshly isolated Tregs [36, 82–85] .A r t i ﬁ c i a lA P C sh a v ea l s o
been used to facilitate the expansion of nTregs in vitro
[86]. Another strategy of in vitro conversion of human
CD4+CD25− non-Treg cells into functional Foxp3+ Tregs
involves the stimulation of the cells with TGFβ and sirolimus
[87]. However, it is estimated that greater numbers of
Tregs might be required to maximise eﬃcacy in solid organ
transplantation, probably in the order of 109 to 1011, when
compared to HSCT [76–78], where fewer Treg numbers
appear to be suﬃcient. Nonetheless, recent protocols have
demonstrated the ability to generate and expand large num-
bers of phenotypically and functionally stable allospeciﬁc
Tregs [88, 89], a method that could be applied readily in
translational medicine.
Finally, knowledge of the pharmacological eﬀects of
immunosuppressive drugs on Treg function and develop-
ment is of outmost importance when designing protocols
involving the administration of Tregs, in order to preempt
a potentiating or minimising eﬀect.
6.3. Is It Antigen Speciﬁcity Important? An important notion
extrapolated from animal work in transplantation tolerance
istheobservationthatantigen-speciﬁcTregsandperhapsthe
most eﬃcient Tregs home to and remain inside secondary
lymphoid tissue or inside the graft rather than in the circula-
tion. In animals, purifying Tregs from these compartments is
feasible, but not in the clinical setting. Thus, purifying Tregs
from peripheral blood for their use in transfer protocols
could lead to the enrichment of less eﬃcient non-antigen-
speciﬁc Tregs, but this is still our compromise. This can
have practical implications as antigen-speciﬁc Tregs appear
to be more powerful to perform immunoregulation than
their polyclonal counterparts [89]. It is also possible that the
in vitro manipulation of Tregs might alter their migratory
capacities, impeding their desired migration to the allograft
or its draining lymph nodes, but it has been demonstrated
that ex vivo expanded Tregs can locate inside the graft and
lymph nodes [88, 89], where they should be able to perform
immunoregulation. The creation of a frozen nTreg cell bank
to permit Treg administration to diﬀerent patients or to be
used if recurrent maintenance Treg infusions are required
would be of practical use. However, cryopreservation of
Tregs is also not an easy task, as it can aﬀect the yield and
health of the cells. In this respect, the cryopreservation of
donor-speciﬁc Treg clones will be more feasible in recipients
of living donor kidney grafts than in deceased donor
transplantation, where the transplant surgery occurs in an
emergency basis and it is practically impossible to generate
donor-speciﬁc Tregs.
It is worth mentioning that donor-speciﬁc Tregs have
been generated in vitro with either direct or indirect
allorecognition capacity. The direct pathway of allorecogni-
tion involves the stimulation of T cells with intact allogeneic
MHC molecules presented by donor APCs, the so-called
“passenger” leukocytes. The direct pathway is a powerful
stimulator of alloresponses, starting as soon as the transplant
is grafted into the recipient. With the migration and eventual
demise of the “passenger” leukocytes, the cells bearing
intact donor-derived MHC molecules, the contribution of
the direct pathway in chronic rejection or triggering acute
episodes of rejection late in transplantation, might not
be as signiﬁcant as the indirect pathway. On the other
hand, the indirect pathway involves the presentation of the
allogeneic determinants via the recipient APCs through the
self-MHC molecules loaded with the peptides from the
allogeneic donor-derived MHC molecules, which is in fact
the conventional way of antigen presentation. This indirect
pathwayisbelievedtobethemostimportantdriveofchronic
rejectionasdependmainlyontheuptakeandpresentationof
the MHC antigens present on the parenchymal cells within
the transplant [90, 91], therefore, allogeneic MHC-derived
antigens are constantly delivered to the immune system. In
fact, administration of Tregs speciﬁc for both the direct and
the indirect pathway of allorecognition was able to prevent
acute rejection episodes as well as chronic rejection changes
in a murine model of skin and cardiac transplantation
preconditioned with sublethal irradiation and BMT, while
Tregs with direct speciﬁcity alone were able to protect only
against acute rejection but not chronic rejection [41]. It
must be emphasised that in this model, BMT alone failed
to protect against rejection, illustrating the importance ofJournal of Transplantation 11
combining strategies in order to secure a highest success rate
for immunoregulatory therapies applicable in the clinical
setting.
From all these observations, it can be concluded that the
diﬀerential generation of Tregs targeting these two diﬀerent
pathways of allorecognition should provide a practical
advantage to target diﬀerent arms of the alloresponse and at
diﬀerent stages posttransplantation. Thus, we can postulate
that donor-speciﬁc Tregs with speciﬁcity to intact allogeneic
MHC molecules [89], the direct pathway, could be used
mainly at induction phases of immunosuppression, while
Tregs with indirect allospeciﬁcity [88]c o u l db eu s e da s
maintenance adjuvants of immunosuppression.
6.4. Potential Hazards of Regulatory T-Cell Administration.
Another concern, given that Tregs appear to perform their
eﬀectorregulatorymechanismsinanantigen-unspeciﬁcway,
the systemic administration of Tregs could cause unwanted
bystanderinactivationofrequiredimmuneresponsesagainst
viruses or other pathogens, as well as for immunosurveil-
lance against cancer. However, no increased risk for these
potential side-eﬀects were observed in the published trials
on HSCT [76–78]. In addition, the use of allospeciﬁc Tregs
should minimise even further such potential risks. A notable
observation that has troubled our minds is the transient
expression of Foxp3 by some human Teﬀsu p o na c t i v a t i o n
[19]. This could lead to the enrichment of undesired Teﬀsi f
Foxp3 expression is used as the Treg-identiﬁcation marker or
surrogatemarkerofTregfunction,withtheriskofadoptively
transferring contaminant Teﬀs that likely could attack the
graft rather that prevent an immune rejection. Similarly,
Tregs may display phenotypic plasticity when in contact
with proinﬂammatory conditions [92, 93]. They have been
shown to be able to transform into pathogenic alloreactive T
cells with a Th17-like phenotype, which brings the danger
of sensitising the recipient instead of promoting tolerance
if the injected Tregs were to lose their phenotype once in
contact with the host immune system [94]. But the ability to
maintain stable functional Tregs for prolong period of times
and being able to perform immunoregulation in animal
models have been published [88, 89]a n do p e n su pb r i g h t
perspectives.
6.5.AreWeReadyThenfortheUseofRegulatoryTCellsforthe
Immunotherapy of Kidney Transplantation? At present, there
is no published evidence on the use of Tregs for solid organ
clinical transplantation. There are many technical, logistic
and ethical barriers to be faced by researchers interested
in Treg-based immunotherapy. Despite encouraging results
and promising protocols and given the complexity of the
immunesystemandthediversityofthemechanismsinvolved
in self-tolerance, it is unlikely that the sole administration
of Tregs could successfully lead to permanent engraftment
of an organ in the absence of immunosuppression. So, we
foresee Treg-therapy, at least at present, as an adjunctive
potential therapy. Nevertheless, a couple of promising trials
have been started on the use of Treg-based therapy for
kidney transplantation, and a few more are expected to
surface in coming years. A Russian group led by Kaabak and
Bykovskai is, at time of writing, performing a clinical trial
testing the role of Treg infusions on kidney transplantation
in children. In their protocol, ex vivo expanded autologous
Tregs are administered at months 1 and 6 posttransplanta-
tion in patients on concurrent immunosuppression regimen
based on alemtuzumab, a CNI and mycophenolate mofetil.
Similarly, the ONE study involves a large eﬀort from four
European countries and the United States of America to
assess the use of nTreg infusions (among other cells with
regulatory capacities) as adjunctive therapy of immunosup-
pression in kidney transplantation. The outcomes of these
trials would be much anticipated. Finally, it is possible that
future alternatives with greater likelihood of inducing graft
tolerance could include hybrid therapies combining Treg
administration with immunoablation and combined kidney
and BMT.
7. Concluding Remarks
It seems to be of importance to explore an association
between certain Treg:Teﬀ proﬁles with clinical parameters,
biomarkers of kidney injury or tolerance, kidney biopsy
ﬁndings, and clinical outcomes in kidney transplantation.
Although there are contradictory reports on the utility of
Tregs for the immune diagnosis and prediction of outcomes
in clinical kidney transplantation, we believe that there is
more compelling evidence supporting the role of Tregs in
the immune diagnosis of acute kidney transplant rejection
and outcomes prediction. In particular, characterisation and
quantiﬁcation of Tregs in patients with SCR on protocol
biopsies or patients with DGF may be useful to help us to
tailortheirimmunosuppressiveregimens,butfurtherstudies
validating such observations should be performed.
Study outcome of the ONE study, the largest inter-
national trial on the use of Treg-based therapy in adult
kidney transplantation, is enthusiastically awaited. However,
before we can use Treg infusions as routine prescriptions
in the wards, few technical diﬃculties in generating large
numbers of a highly pure population of autologous Tregs
have to be resolved. To be used in the clinical setting,
these Tregs should be allospeciﬁc and possess a stable Treg
phenotype with prime regulatory properties, so as to avoid
excessive bystander suppression and potential undesired
predisposition to infections or neoplasias.
Contrary to the commonly held belief, it appears that
Tregs may not be a deﬁnitive marker for long-term engraft-
ment and/or graft tolerance and might not be “the clue” in
our search for tolerance. Although it seems a long way to go
in ﬁnding the desperately-awaited “holy-grail,” the crusade
for transplantation tolerance shall never cease.
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